The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Sjogren's syndrome usually occurs in women in their 50s and 60s. According to the 2023 data, 15,818 patients, or more than ...

Three patients in the Yescarta trial died from severe cases of cytokine release syndrome (CRS), which can occur when proteins called cytokines are released by active white blood cells and cause ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

The Jackson Laboratory has developed a new platform to provide a fast, accurate and reliable method for screening novel immunotherapy treatments for efficacy and cytokine release syndrome.

Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) ...

In a live virtual event, Attaya Suvannasankha, MD, discussed the MajesTEC-1 trial of teclistamab and approaches to mitigation ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

One concern is that insertional mutagenesis of the lentiviral DNA payload in in vivo CAR-Ts may cause secondary cancers.

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and ...

MONMOUTH JUNCTION, N.J., March 20, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat ...